Boundless Bio Inc. (Nasdaq: BOLD), a clinical-stage oncology company, reported financial results for the second quarter ending June 30, 2025. The company announced a net loss of $15.7 million, compared to a net loss of $17.0 million for the same period in 2024. Research and Development expenses decreased to $12.2 million, down from $14.7 million in the previous year. General and Administrative expenses slightly increased to $4.8 million from $4.7 million in the second quarter of 2024. The company maintains a strong cash position, with cash, cash equivalents, and short-term investments totaling $127.1 million as of June 30, 2025. This financial health is expected to support operations into the first half of 2028, allowing for expected proof-of-concept clinical readouts for its programs. In terms of business updates, Boundless Bio has opened the combination arm of the POTENTIATE trial for enrollment and is on track to submit an investigational new drug application for BBI-940 in the first half of 2026. The company is focused on advancing its BBI-355/BBI-825 combination in the clinic and progressing its novel kinesin program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-102386), on August 05, 2025, and is solely responsible for the information contained therein.
Comments